Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier were the only age cohort in the U.S. increasing their year-over-year ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

The rush for weight loss drugs like Wegovy and diabetes drugs like Ozempic (which is also used for weight loss) has drained ...

Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Novo Nordisk is alarmed by safety risks from compounded versions of its weight-loss and diabetes drugs, Wegovy and Ozempic, ...